Why the study?
Does intravenous dextran 70 cause dextran-induced anaphylactoid reactions in gynaecological and obstetric patients undergoing major surgery?
Does intravenous dextran 70 cause dextran-induced anaphylactoid reactions in gynaecological and obstetric patients undergoing major surgery?
The risks of severe anaphylactoid reactions from intravenous dextran 70 exceed the benefits of thromboembolism prophylaxis in gynaecological and obstetric patients.
A prospective study of dextran-induced anaphylactoid reactions (DIAR) in 5745 gynaecological and obstetric patients who received dextran 70 solution intravenously while undergoing major surgery revealed 8 patients who had Grade I or II reactions and 7 patients who had Grade III or IV reactions. The incidence of severe reactions was 1:821 patients treated. The overall incidence of reactions per patient treated was 1:383. One neonatal death followed a dextran-induced cardiac arrest in a woman about to undergo caesarean section. The risks of dextran 70 treatment exceeded the risks of thromboembolism in these patients.
No takes yet. Share an insight, caveat, or question.
John Paull (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: